Jamin Koo, PhD, Stanford University, Stanford, CA, shares some insights into a study which uses machine learning-assisted risk stratification to predict the outcomes of patients with newly diagnosed multiple myeloma (NDMM) being treated with bortezomib, lenalidomide and dexamethasone (VRd). This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.